66th ASH Annual Meeting: 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: It's All About the Money!

Symposia: Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies Oral and Poster Abstracts
Oral

Bleeding and Clotting, Bleeding disorders, Research, Adult, Clinical Practice (Health Services and Quality), Hemophilia, Bispecific Antibody Therapy, Clinical Research, Health outcomes research, Pediatric, Education, Diseases, Therapy sequence, Treatment Considerations, Biological therapies, Young adult , Technology and Procedures, Human, Study Population, Maternal Health, Pathology

Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)

Moderators:

Madhvi Rajpurkar, MD, and Lisa Baumann Kreuziger, MD, MS, ARRAY(0xeb6d6f4)

Disclosures:

Baumann Kreuziger: CSL Behring: Research Funding; Takeda: Research Funding; Sanofi: Research Funding; Veralox: Research Funding.

2:00 PM

277

Sex, Lies, and Iron Deficiency in 2024: Cost-Effectiveness of Screening Ferritin Thresholds for the Treatment of Iron Deficiency in Women of Reproductive Age

Daniel Wang¹, Samira Glaeser-Khan, BS¹^*, Daniel Y Wang²^*, Ranya Moshashaian Asl³^*, Karthik Chetlapalli, MS, BS¹, Satoko Ito, MD, PhD⁴, Adam Cuker, MD MS⁵ and George Goshua, MD, MSc⁶

¹Yale School of Medicine, New Haven, CT
²Yale College, New Haven
³University of Vermont Larner College of Medicine, Burlington
⁴Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
⁵Department of Medicine and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
⁶Hematology-Oncology & Yale CORE, Yale School of Medicine & Yale Cancer Center, New Haven, CT

2:15 PM

278

Characterizing the Healthcare Resource Utilization and Costs of Hereditary Hemorrhagic Telangiectasia (HHT)

Hanny Al-Samkari, MD^1,2, Tracy Mayne, PhD³^*, Sandra Texeira, PhD⁴^*, Marianne S. Clancy, RDH, MPA⁵^* and Eric Duhaime, MBA⁴^*

¹Harvard Medical School, Boston, MA
²Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA
³Slipstream IT, San Francisco, CA
⁴Diagonal Therapeutics, Cambridge, MA
⁵Cure HHT, Monkton, MD

2:30 PM

279

Health Equity Impacts of Funding Emicizumab in People with Severe Hemophilia a in the US: An Aggregate Distributional Cost-Effectiveness Analysis

Thomas Majda¹^*, Janet S Lee¹^*, Randall Curtis, MBA²^* and Stacey L Kowal, MS¹^*

¹Genentech, Inc., South San Francisco, CA
²Factor VIII Computing, Berkeley, CA

2:45 PM

280

Strategies to Optimize Overutilization of Provider-Ordered Peripheral Blood Smear Review in an University Hospital Setting

Bhavesh Mohan Lal, MD¹, Jacob T Wooldridge²^*, Mamatha Gaddam, MD³, Ankur Varma, MD³, Ginell R. Post, MD, PhD⁴^* and Muthu V. Kumaran, MD³^*

¹University of Arkansas for Medical Sciences, Little Rock, Little Rock, AR
²University of Arkansas for Medical Sciences, Little Rock
³University of Arkansas for Medical Sciences, Little Rock, AR
⁴Univ. of Arkansas for Medical Sciences, Little Rock, AR

3:00 PM

281

Cost-Effectiveness of Oral Versus Intravenous First-Line Treatment of Severe Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding

Daniel Wang¹, Daniel Y Wang²^*, Samira Glaeser-Khan, BS¹^*, Ranya Moshashaian Asl³^*, Karthik Chetlapalli, MS, BS¹, Satoko Ito, MD, PhD⁴, Adam Cuker, MD MS⁵ and George Goshua, MD, MSc⁶

3:15 PM

282

Use of American Society of Hematology ITP Guidelines to Decrease Hospitalizations and IVIG Use Among Children Presenting with Acute ITP to a Tertiary Care Pediatric Hospital – a Quality Improvement Project

Sanjay J. Shah, MBBS^1,2, Mona Nourani³^* and Christine M. Knoll, MD⁴^*

¹Department of Child Health, Phoenix Children’s Hospital, University of Arizona College of Medicine, Chandler, AZ
²Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, AZ
³Department of Child Health, University of Arizona School of Medicine, Phoenix Arizona, AZ
⁴Phoenix Children's Hospital, Phoenix, AZ

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

901.O1.6 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: It's All About the Money!